The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater with dupilumab vs. placebo, according to findings from a win ratio analysis ...

NEW YORK — The Detroit Pistons may not have history on their side, but they’re not out of it just yet. The Pistons held off the New York Knicks on Tuesday night in a 106-103 victory ...

Eosinophilic esophagitis (EoE) is a multifaceted disease marked by diverse clinical features, including variations in age of onset, symptoms, disease progression, comorbid conditions, and treatment ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Apogee conducted third-party quantitative market research in April 2025 and asked US patients and physicians the likelihood that they would switch to APG777 from their current or previous biologic ...